Phase 1b safety study of xevinapant, weekly cisplatin, and radiotherapy in participants with unresected LA SCCHN
MS202359_0025
Phase 1 other active
Quick answer
Phase 1b safety study of xevinapant, weekly cisplatin, and radiotherapy in participants with unresected LA SCCHN for Locally Advanced Squamous Cell Carcinoma of the Head and Neck is a Phase 1 program (other) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Locally Advanced Squamous Cell Carcinoma of the Head and Neck
- Phase
- Phase 1
- Modality
- other
- Status
- active